To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded by General Manager Yunshu Zhou. Zhou has served in various roles at the Lianyungang-based company since 1995. Hengrui markets a variety of drugs including classical Hodgkin lymphoma therapy camrelizumab (SHR-1210), an anti-PD-1 antibody, in China.

Olivier Brandicourt will join Blackstone Group as a senior adviser, a source familiar with the

Read the full 846 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE